Which of the following describes a potential risk associated with the discontinuation of Apixaban?

Which of the following describes a potential risk associated with the discontinuation of Apixaban?

• A. Increased risk of infection
• B. Increased risk of thrombotic events
• C. Increased risk of liver damage
• D. Increased risk of hypertension

Answer: (B)

Discontinuing Apixaban, an anticoagulant medication, is associated with an increased risk of thrombotic events. Apixaban works by inhibiting factor Xa in the coagulation cascade, thereby reducing the ability of the blood to clot. If a patient stops taking Apixaban suddenly or without proper medical guidance, there is a significant chance that the protective anticoagulant effects will be lost. This can lead to an increased risk for conditions such as stroke or deep vein thrombosis, as the blood becomes more prone to clotting without the medication's influence. Understanding the importance of consistent anticoagulation therapy is critical, especially in patients with conditions such as atrial fibrillation or those who have undergone surgeries where blood clots pose a significant risk. Therefore, careful management is essential when considering the discontinuation of Apixaban to mitigate the risk of thrombotic complications.

Discontinuing Apixaban, an anticoagulant medication, is associated with an increased risk of thrombotic events. Apixaban works by inhibiting factor Xa in the coagulation cascade, thereby reducing the ability of the blood to clot. If a patient stops taking Apixaban suddenly or without proper medical guidance, there is a significant chance that the protective anticoagulant effects will be lost. This can lead to an increased risk for conditions such as stroke or deep vein thrombosis, as the blood becomes more prone to clotting without the medication's influence.

Understanding the importance of consistent anticoagulation therapy is critical, especially in patients with conditions such as atrial fibrillation or those who have undergone surgeries where blood clots pose a significant risk. Therefore, careful management is essential when considering the discontinuation of Apixaban to mitigate the risk of thrombotic complications.